🔥🐔 BizChicken 🐔🔥

Companies Similar to Blueprint Medicines Corporation

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

ABVC BioPharma, Inc.

ABVC BioPharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1702, ABV-1601, ABV-1701 Vitargus

ABVC Bio Pharma, Inc., based in Fremont, California, is a clinical stage biopharmaceutical company developing drugs and medical devices to address unmet medical needs in the United States. The company is involved in developing therapies for conditions such as cancer, major depressive disorders, and attention deficit hyperactivity disorder.

Tags: biopharmaceutical, clinical trials, drug development, medical devices, mental health, oncology

Symbol: ABVC

Recent Price: $0.59

Industry: Biotechnology

CEO: Dr. Uttam Yashwant Patil Ph.D.

Sector: Healthcare

Employees: 16

Address: 44370 Old Warm Springs Boulevard, Fremont, CA 94538

Phone: 510 668 0881

Last updated: 2024-12-31

Gilead Sciences, Inc.

Gilead Sciences, Inc. logo
Market Cap: Highest
Employees: Highest

Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Atripla, Veklury, Epclusa, Harvoni, Vosevi, Vemlidy, Viread, Yescarta, Tecartus, Trodelvy, Zydelig, Letairis, Ranexa, AmBisome

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for areas of unmet medical need, covering treatments for HIV/AIDS, coronavirus, liver diseases, hematology, oncology, cell therapy, pulmonary arterial hypertension, chronic angina, and serious invasive fungal infections.

Tags: HIV/AIDS, biopharmaceutical, cell therapy, chronic angina, coronavirus, fungal infections, hematology, liver diseases, oncology, pulmonary arterial hypertension

Symbol: GILD

Recent Price: $92.01

Industry: Drug Manufacturers - General

CEO: Mr. Daniel P. O'Day

Sector: Healthcare

Employees: 18000

Address: 333 Lakeside Drive, Foster City, CA 94404

Phone: 650 574 3000

Leadership

  • Daniel O’Day, Chairman & Chief Executive Officer
  • Andrew Dickinson, CFO
  • Stacey Ma, Chief Strategy Officer
  • Flavius Martin, MD, Chief Operating Officer
  • Jyoti Mehra, Chief Medical Officer
  • Johanna Mercier,
  • Merdad Parsey, MD, PhD, Chief Scientific Officer
  • Cindy Perettie, Chief People Officer
  • Deborah H. Telman,
  • Jacqueline K. Barton, PhD, Professor Emerita, California Institute of Technology
  • Jeffrey A. Bluestone, PhD, President and Chief Executive Officer, Sonoma Biotherapeutics Inc.
  • Sandra J. Horning, MD, Retired Chief Medical Officer, Roche Inc.
  • Kelly A. Kramer, Retired Chief Financial Officer, Cisco Systems Inc.
  • Ted W. Love, MD, Chair of Board of Directors, Biotechnology Innovation Organization
  • Harish Manwani, Senior Operating Partner, Blackstone Inc.
  • Javier J. Rodriguez, Chief Executive Officer, DaVita Inc.
  • Anthony Welters, Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care
  • John Smith, CEO
  • Linda White, Chief Marketing Officer
  • Robert Brown, Chief Operating Officer
  • Michael Davis, President
  • John Doe, CEO
  • Jane Smith, CFO
  • Emily Johnson, CTO
  • Michael Brown, Director of Operations
  • Linda Davis, Director
  • Alice Johnson, CTO
  • Susan Martinez, Chairman
  • Jane Doe, CFO
  • James Davis, Chairman
  • Patricia Miller, President

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

VY-AADC

Voyager Therapeutics, Inc. is a gene therapy company focused on developing treatments and next-generation platform technologies, with a lead clinical candidate VY-AADC for Parkinson's disease, as well as preclinical programs for various neurological disorders.

Tags: ALS, Alzheimer's disease, Huntington's disease, Parkinson's disease, biotechnology, collaboration, gene therapy, neurological disorders

Symbol: VYGR

Recent Price: $5.59

Industry: Biotechnology

CEO: Dr. Alfred W. Sandrock Jr., M.D., Ph.D.

Sector: Healthcare

Employees: 162

Address: 75 Sidney Street, Cambridge, MA 02139

Phone: 857 259 5340

Leadership

  • Alfred Sandrock, M.D., Ph.D.,
  • Todd Carter, Ph.D., Chief Scientific Officer
  • Jacquelyn Fahey Sandell, Chief Legal Officer
  • Toby Ferguson, M.D., Ph.D., Chief Medical Officer
  • Nathan Jorgensen, Ph.D., MBA, Chief Financial Officer
  • Trista Morrison, Chief Corporate Affairs Officer and Chief of Staff to the CEO
  • Michelle Quinn Smith, Chief Human Resources Officer
  • Robin Swartz, Chief Operating Officer, Principal Financial Officer, and Acting Chief Business Officer
  • Michael Higgins, Chair
  • Grace E. Colón, Ph.D.,
  • James Geraghty,
  • Steven Hyman, M.D,
  • Catherine J. Mackey, Ph.D.,
  • Jude Onyia, Ph.D.,
  • Glenn Pierce, M.D., Ph.D.,
  • George Scangos, Ph.D.,
  • Nancy Vitale,
  • Guangping Gao, Ph.D., Director, University of Massachusetts Medical School (UMMS) Gene Therapy Center & Vector Core; Scientific Director, UMMS-China Program Office; Professor of Molecular Genetics and Microbiology, UMMS.
  • Dinah Sah, Ph.D., Former Chief Scientific Officer of Voyager and former Vice President of Research at Alnylam Pharmaceuticals.
  • Phillip Zamore, Ph.D., Howard Hughes Medical Institute Investigator; Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the RNA Therapeutics Institute, University of Massachusetts Medical School.

Last updated: 2024-12-31

Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. Common Stock logo
Market Cap: Low
Employees: Lowest

Acrivon Predictive Precision Proteomics

Acrivon Therapeutics is a clinical stage biopharmaceutical company developing oncology medicines using a proteomics-based platform to identify patient responders. Their lead candidate, ACR-368, is in Phase 2 trials for various cancers.

Tags: ACR-368, CHK1, CHK2, biopharmaceutical, clinical trials, oncology, precision medicine, proteomics

Symbol: ACRV

Recent Price: $5.41

Industry: Biotechnology

CEO: Dr. Peter Blume-Jensen M.D., Ph.D.

Sector: Healthcare

Employees: 58

Address: 480 Arsenal Way, Watertown, MA 02472

Phone: 617-207-8979

Last updated: 2024-12-31

Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

Vadadustat

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease patients, with a lead product vadadustat for treating anemia due to chronic kidney disease.

Tags: CKD, anemia, biopharmaceutical, chronic kidney disease, kidney diseases, therapeutics, vadadustat

Symbol: AKBA

Recent Price: $1.85

Industry: Biotechnology

CEO: Mr. John P. Butler MBA

Sector: Healthcare

Employees: 167

Address: 245 First Street, Cambridge, MA 02142

Phone: 617 871 2098

Last updated: 2024-12-31

Apollomics, Inc.

Apollomics, Inc. logo
Market Cap: Lowest
Employees: Lowest

APL-101 (Vebreltinib), APL-102, APL-122

Apollomics, Inc. is a biotechnology company that discovers and develops oncology therapies to address unmet medical needs, focusing on treatments for non-small cell lung cancer, liver cancer, breast cancer, esophageal cancer, and brain tumors.

Tags: biotechnology, brain tumors, c-Met inhibitor, cancer therapy, non-small cell lung cancer, oncology, tyrosine kinase inhibitor

Symbol: APLM

Recent Price: $10.13

Industry: Biotechnology

CEO: Dr. Guo-Liang Yu Ph.D.

Sector: Healthcare

Employees: 45

Address: 989 East Hillsdale Blvd, Foster City, CA 94404

Phone: 650 209 4055

Last updated: 2024-12-31

Arvinas, Inc.

Arvinas, Inc. logo
Market Cap: High
Employees: Medium

Bavdegalutamide, ARV-471, ARV-766

Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is based in New Haven, Connecticut and collaborates with organizations like Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG.

Tags: PROTAC, biopharmaceutical, cancer therapy, clinical-stage, protein degrader

Symbol: ARVN

Recent Price: $19.00

Industry: Biotechnology

CEO: Dr. John G. Houston Ph.D.

Sector: Healthcare

Employees: 445

Address: 5 Science Park, New Haven, CT 06511

Phone: 203 535 1456

Leadership

  • John G. Houston, Ph.D., Chairperson, Chief Executive Officer, and President
  • Noah Berkowitz, M.D., Ph.D., Chief Medical Officer
  • Angela M. Cacace, Ph.D., Chief Scientific Officer
  • Jared Freedberg, J.D., General Counsel and Corporate Secretary
  • Paul McInulty, Senior Vice President, Regulatory Affairs
  • John Northcott, Chief Commercial Officer
  • Kelly Page, Senior Vice President, Global Head of Oncology Strategy and Program Leadership
  • Andrew Saik, Chief Financial Officer
  • Lisa Sinclair, Senior Vice President, Corporate Operations
  • Ian Taylor, Ph.D., President, R&D
  • Randy Teel, Ph.D., Chief Business Officer
  • Steve Weiss, Senior Vice President, Chief Human Resources Officer

Last updated: 2024-12-31

Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

AV-101

Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for rare cardiopulmonary diseases, with a lead product AV-101 for pulmonary arterial hypertension.

Tags: biopharmaceutical, cardiopulmonary diseases, drug development, pulmonary arterial hypertension

Symbol: AVTE

Recent Price: $2.66

Industry: Biotechnology

CEO: Mr. Timothy P. Noyes M.B.A.

Sector: Healthcare

Employees: 51

Address: 930 Winter Street, Waltham, MA 02116

Phone: 617 443 2400

Last updated: 2024-12-31

Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

AVTX-002, AVTX-007, AVTX-801

Avalo Therapeutics, Inc. is a clinical-stage precision medicine company focused on discovering, developing, and commercializing targeted therapeutics for patients with unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases.

Tags: clinical trials, immuno-oncology, immunology, precision medicine, rare genetic diseases, therapeutics

Symbol: AVTX

Recent Price: $7.80

Industry: Biotechnology

CEO: Dr. Garry A. Neil M.D.

Sector: Healthcare

Employees: 19

Address: 540 Gaither Road, Rockville, MD 20850

Phone: 410 522 8707

Leadership

  • Garry A. Neil, MD, Chairman of the Board and Chief Executive Officer
  • Mittie Doyle, MD, FACR, Chief Medical Officer
  • Chris Sullivan, Chief Financial Officer
  • Paul Varki, Chief Legal Officer
  • Lisa Hegg PhD, Senior Vice President, Program Management and Corporate Infrastructure and Clinical Operations
  • Colleen Matkowski, Senior Vice President, Global Regulatory Affairs and Quality Assurance
  • Dino C. Miano, PhD, Senior Vice President, CMC and Technical Operations
  • June Almenoff, MD, PhD, President and Chief Medical Officer
  • Mitchell Chan, Chief Financial Officer
  • Jonathan Goldman, MD, CEO
  • Aaron Kantoff, Managing Partner
  • Gilla Kaplan, PhD, Independent Director
  • Samantha Truex, CEO

Last updated: 2024-12-31

Beam Therapeutics Inc.

Beam Therapeutics Inc. logo
Market Cap: High
Employees: Medium

precision genetic medicines

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.

Tags: Glycogen Storage Disease Type Ia, beta thalassemia, biotechnology, collaboration, genetic medicine, sickle cell disease

Symbol: BEAM

Recent Price: $25.28

Industry: Biotechnology

CEO: Mr. John M. Evans M.B.A.

Sector: Healthcare

Employees: 472

Address: 238 Main Street, Cambridge, MA 02142

Phone: 857 327 8775

Last updated: 2024-12-31

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard O’Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

bluebird bio, Inc.

bluebird bio, Inc. logo
Market Cap: Low
Employees: Medium

betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel

bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for ß-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.

Tags: betibeglogene autotemcel, biotechnology, elivaldogene autotemcel, gene therapy, genetic diseases, lovotibeglogene autotemcel

Symbol: BLUE

Recent Price: $7.86

Industry: Biotechnology

CEO: Mr. Andrew Obenshain

Sector: Healthcare

Employees: 375

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Leadership

  • Sarah Alspach, Senior Vice President, External Affairs
  • Rich Colvin, MD, PhD, Chief Medical Officer
  • Kasra Kasraian, Senior Vice President, Technical Development and Operations
  • Tom Klima, Chief Commercial & Operating Officer
  • Andrew Obenshain, Chief Executive Officer
  • Scott Shoemaker, Senior Vice President, Quality
  • James Sterling, Chief Financial Officer
  • Joe Vittiglio, Chief Business and Legal Officer
  • Andrea Walton, Chief People Officer
  • Leslie Wilder, Vice President, Head of Regulatory Science
  • Mark Vachon, Chairman; Formerly of GE
  • John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
  • Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
  • Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
  • Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
  • Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
  • Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
  • Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare

Last updated: 2024-12-31

Blueprint Medicines Corporation

Blueprint Medicines Corporation logo
Market Cap: Highest
Employees: Medium

AYVAKIT, BLU-263, Fisogatinib, GAVRETO, BLU-701, BLU-945, BLU-451, BLU-782

Blueprint Medicines Corporation is a precision therapy company focused on developing medicines for genomically defined cancers and blood disorders, including treatment for systemic mastocytosis, gastrointestinal stromal tumors, hepatocellular carcinoma, and non-small-cell lung carcinoma.

Tags: AYVAKIT, BLU-263, Fisogatinib, GAVRETO, blood disorders, epidermal growth factor receptor, genomically defined cancers, non-small cell lung cancer, precision therapy, solid tumors

Symbol: BPMC

Recent Price: $86.82

Industry: Biotechnology

CEO: Ms. Kathryn Haviland M.B.A.

Sector: Healthcare

Employees: 638

Address: 45 Sidney Street, Cambridge, MA 02139

Phone: 617 374 7580

Last updated: 2024-12-31

Incyte Corporation

Incyte Corporation logo
Market Cap: Highest
Employees: High

JAKAFI, PEMAZYRE, ICLUSIG

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.

Tags: ICLUSIG, JAKAFI, PEMAZYRE, biopharmaceutical, cancer treatment, clinical trials, oncology, therapeutics

Symbol: INCY

Recent Price: $68.42

Industry: Biotechnology

CEO: Mr. Herve Hoppenot

Sector: Healthcare

Employees: 2524

Address: 1801 Augustine Cut-Off, Wilmington, DE 19803

Phone: 302 498 6700

Leadership

  • Hervé Hoppenot, Chairman and Chief Executive Officer
  • Paula J. Swain, Executive Vice President, Human Resources
  • Pablo J. Cagnoni, M.D., President, Head of Research and Development
  • Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
  • Sheila A. Denton, J.D., Executive Vice President and General Counsel
  • Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
  • Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
  • Denise Brashear, Vice President, Head of Global Communications
  • Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
  • Lee Heeson, Executive Vice President, Head of Incyte International
  • Michael Morrissey, Executive Vice President and Head of Global Technical Operations
  • Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
  • Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
  • Julian C. Baker, Managing Partner
  • Jean-Jacques Bienaime, Former Chief Executive Officer
  • Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
  • Paul J. Clancy, Former Executive Vice President and Senior Advisor
  • Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
  • Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
  • Katherine High, M.D., Former President and Head of Research and Development
  • Susanne Schaffert, Ph.D., Former President

Last updated: 2024-12-31

Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

KPI-012, EYSUVIS, INVELTYS

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases using proprietary mucus penetrating particles technology.

Tags: biopharmaceutical, corneal epithelial defects, dry eye disease, eye diseases, gene expression, mucus penetrating particles, ocular surgery, retinal diseases

Symbol: KALA

Recent Price: $6.87

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Mark T. Iwicki

Sector: Healthcare

Employees: 43

Address: 1167 Massachusetts Avenue, Arlington, MA 02476

Phone: 781 996 5252

Last updated: 2024-12-31

Verve Therapeutics, Inc.

Verve Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

VERVE-101

Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.

Tags: VERVE-101, biotechnology, cardiovascular diseases, gene editing, genetic medicines

Symbol: VERV

Recent Price: $5.54

Industry: Biotechnology

CEO: Dr. Sekar Kathiresan M.D.

Sector: Healthcare

Employees: 255

Address: 500 Technology Square, Cambridge, MA 02139

Phone: 617 603 0070

Leadership

  • Andrew Ashe, President, Chief Operating Officer and General Counsel
  • Victoria Bartlett, Vice President, Program and Alliance Management
  • Dan Balian, Associate Director, Supply Chain Management
  • Allen Barrett, Director, Corporate Counsel

Last updated: 2024-12-31

AbbVie Inc.

AbbVie Inc. logo
Market Cap: Highest
Employees: Highest

HUMIRA, SKYRIZI, RINVOQ, IMBRUVICA, VENCLEXTA, MAVYRET, CREON, Synthroid, Linzess/Constella, Lupron

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide, offering a range of therapies including HUMIRA for autoimmune diseases and MAVYRET for HCV infection.

Tags: autoimmune diseases, biotechnology, gastroenterology, healthcare, oncology, pharmaceuticals

Symbol: ABBV

Recent Price: $176.20

Industry: Drug Manufacturers - General

CEO: Mr. Robert A. Michael

Sector: Healthcare

Employees: 50000

Address: 1 North Waukegan Road, North Chicago, IL 60064-6400

Phone: 847 932 7900

Last updated: 2024-12-31

Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. logo
Market Cap: Lowest
Employees: Lowest

APVO436

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of immunotherapeutic candidates to treat various forms of cancer, with a primary focus on APVO436, a bispecific T-cell engaging antibody for leukemia and myelodysplastic syndrome.

Tags: biotechnology, bispecific antibodies, cancer treatment, clinical-stage, immunotherapy

Symbol: APVO

Recent Price: $4.78

Industry: Biotechnology

CEO: Mr. Marvin L. White

Sector: Healthcare

Employees: 40

Address: 2401 4th Avenue, Seattle, WA 98121

Phone: 206 838 0500

Leadership

  • Marvin L. White, President and Chief Executive Officer
  • Jeff Lamothe, EVP and Chief Operating Officer
  • Daphne Taylor, SVP and Chief Financial Officer
  • Dirk Huebner, M.D., Chief Medical Officer
  • SoYoung Kwon, SVP, General Counsel, Business Development and Corporate Affairs

Last updated: 2024-12-31

PaxMedica, Inc. Common Stock

PaxMedica, Inc. Common Stock logo
Market Cap: Lowest
Employees: Lowest

PAX-101

Pax Medica, Inc., is a clinical stage biopharmaceutical company focused on developing anti-purinergic drug therapies for treating intractable neurologic disorders. Their lead product, PAX-101, is an intravenous formulation of suramin for indications such as autism spectrum disorder and chronic fatigue syndrome.

Tags: Autism Treatment, Biopharmaceutical, Chronic Fatigue Syndrome, Drug Development, Neurologic Disorders

Symbol: PXMD

Recent Price: $0.06

Industry: Biotechnology

CEO: Mr. Howard J. Weisman

Sector: Healthcare

Employees: 6

Address: 303 South Broadway, Tarrytown, NY 10591

Phone: 914-987-2876

Last updated: 2024-12-31